Clinical Trials

Cohort study evaluating efficacy of bevacizumab plus paclitaxel in patients with HER2-negative inoperable or metastatic breast cancer(JBCRG-C05)

State Suspended
Objectives The purpose of this study is to evaluate the efficacy and safety of bevacizumab combined with paclitaxel as first or second line chemotherapy in clinical practice in HER2 negative inoperable or metastatic breast cancer patients.
Endpoints Primary outcomes: Overall Survival(OS)
Secondary outcomes: Response Rate(RR), Progression Free Survival(PFS), Safety
Trial Period 5 years 2012.11.1 - 2017.10.31
Lead Principal Investigator 1)Yutaka Yamamoto,Kumamoto University Hospital
2)Hiroyasu Yamashiro, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
No. of Institutions
Target Sample Size 750(cohort A:500, cohort B:250)
Regimen bevacizumab combined with paclitaxel
Source of Funding Chugai Pharmaceutical Co., Ltd.
Conference Presentation
Articles and Publications
UMIN-ID UMIN000009086
  UMIN-ID : This clinical trial is registered in UMIN-CTR (Medical Information, University hospital Medical Information Network - Clinical Trials Registry). Please search for this trial by UMIN-ID in the following URL.
Memo Protocol was revised to ver1.1 on Oct.3,2016

< Back to List